Dyadic to Present at BioProcess International
September 12 2023 - 4:30PM
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:
DYAI), a global biotechnology company focused on building
innovative microbial platforms to address the growing demand for
global protein bioproduction and unmet clinical needs for
effective, affordable and accessible biopharmaceutical products for
human and animal health, and alternative proteins for food,
nutrition and wellness, today announced that Joseph Hazelton, Chief
Business Officer of Dyadic will be presenting at BioProcess
International.
BioProcess International, September 19-21,
2023Boston Convention and Exhibition Center, Boston,
MAPresentation: Vaccine Development and
Manufacturing“C1 Gene Expression Platform: Rapid, High Yield and
Lower Cost Way to Develop and Manufacture
Biologics”Time: Wednesday, September 20, 2023,
9:50 AM – 10:10 AM ET
If you would like to connect with Dyadic at this
event, you may request a one-on-one meeting at jlavalley@dyadic.com
or you can connect online through the partnering portal provided
upon registration to the event.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company focused on building innovative microbial
platforms to address the growing demand for global protein
bioproduction and unmet clinical needs for effective, affordable,
and accessible biopharmaceutical products and alternative proteins
for human and animal health.
Dyadic’s gene expression and protein production
platforms are based on the highly productive and scalable fungus
Thermothelomyces heterothallica (formerly Myceliophthora
thermophila). Our lead technology, C1-cell protein production
platform, is based on an industrially proven microorganism (named
C1), which is currently used to speed development, lower production
costs, and improve performance of biologic vaccines and drugs at
flexible commercial scales for the human and animal health markets.
Dyadic has also developed the Dapibus™ filamentous fungal
based microbial protein production platform to enable the rapid
development and large-scale manufacture of low-cost proteins,
metabolites, and other biologic products for use in
non-pharmaceutical applications, such as food, nutrition, and
wellness.
With a passion to enable our partners and
collaborators to develop effective preventative and therapeutic
treatments in both developed and emerging countries, Dyadic is
building an active pipeline by advancing its proprietary microbial
platform technologies, including our lead asset DYAI-100 COVID-19
vaccine candidate, as well as other biologic vaccines, antibodies,
and other biological products.
To learn more about Dyadic and our commitment to
helping bring vaccines and other biologic products to market
faster, in greater volumes and at lower cost, please visit
http://www.dyadic.com.
Safe Harbor
Regarding Forward-Looking
StatementsThis press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, including those regarding Dyadic International’s
expectations, intentions, strategies, and beliefs pertaining to
future events or future financial performance, such as the success
of our clinical trial and interest in our protein production
platforms, our research projects and third-party collaborations, as
well as the availability of necessary funding. Actual events or
results may differ materially from those in the forward-looking
statements because of various important factors, including those
described in the Company’s most recent filings with the SEC. Dyadic
assumes no obligation to update publicly any such forward-looking
statements, whether because of new information, future events or
otherwise. For a more complete description of the risks that could
cause our actual results to differ from our current expectations,
please see the section entitled “Risk Factors” in Dyadic’s annual
reports on Form 10-K and quarterly reports on Form 10-Q filed with
the SEC, as such factors may be updated from time to time in
Dyadic’s periodic filings with the SEC, which are accessible on the
SEC’s website and at www.dyadic.com.
Contact:
Dyadic International, Inc.Ping W. RawsonChief
Financial OfficerPhone: (561) 743-8333Email: ir@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2024 to May 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From May 2023 to May 2024